Press Releases

Here you can read our press releases and download them as PDF-file.

13.09.2018

Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies

  • Boehringer Ingelheim exercises its option to acquire all shares of oncolytic virus company ViraTherapeutics
  • ViraTherapeutics will operate in Innsbruck, Austria as a distinct unit of Boehringer Ingelheim’s Discovery Research organization, maintaining its innovative biotech heritage and close conn...

05.03.2018

ViraTherapeutics starts second oncolytic virus development program with Boehringer Ingelheim

  • Long-term collaboration with Boehringer Ingelheim to be expanded with a VSV
  • platform-based second oncolytic virus development candidate
  • Boehringer Ingelheim will cover all research and development costs for the new virus development candidate
  • Joint development of ViraTherapeutics’ lead can...

30.05.2017

ViraTherapeutics appoints Heinz Schwer as CEO

Innsbruck, Austria, May 30, 2017 – ViraTherapeutics, a biopharmaceutical company developing promising innovative virus-based immunotherapeutics, today announced the appointment of Dr. Heinz Schwer as CEO. He takes over the position from interim CEO and co-founder Prof. Dr. Dorothee von Laer, who w...

26.09.2016

Boehringer Ingelheim boosts immune-oncology pipeline through collaboration with ViraTherapeutics

New long-term collaboration to develop next generation oncolytic virus platform and lead candidate VSV-GP

Potential transaction value of up to EUR 210 million; co-funding of development activities and option to acquire ViraTherapeutics

Innsbruck, Austria, and Ingelheim, Germany, September 2...

05.11.2015

Fortgeschrittenen Krebs mit Viren gezielt bekämpfen

ViraTherapeutics GmbH eröffnet neues Forschungslabor in Innsbruck

Das österreichische Biotechnologieunternehmen „ViraTherapeutics GmbH“ entwickelt eine weltweit neue Behandlung von Tumoren auf Basis krebstötender (onkolytischer) Viren. Auf dem langjährigen Weg zur einsetzbaren Therapie gege...

23.06.2015

ViraTherapeutics Raises €3.6 million in the First Closing of a Series A Financing Round to Advance its Novel Oncolytic Virus Platform

Funds will be used to progress ViraT’s lead product VSV-GP towards clinical proof of concept in patients with solid tumors.

Innsbruck, Austria, 23 June 2015 - ViraTherapeutics GmbH (ViraT), a privately held biopharmaceutical company developing cancer immunotherapies based on oncolytic (cancer-des...